Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China flag China · Delayed Price · Currency is CNY
13.82
+0.21 (1.54%)
Oct 30, 2026, 3:00 PM CST

SHA:600535 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
7,9108,1478,4688,6368,6067,898
Other Revenue
89.189.129.8137.7131.1953.86
7,9998,2368,4988,6748,6377,952
Revenue Growth
-4.15%-3.08%-2.03%0.42%8.62%-41.43%
Cost of Revenue
2,5732,7432,8102,8853,1472,682
Gross Profit
5,4265,4945,6885,7895,4905,269
Selling, General & Admin
3,0143,3063,3343,3263,2673,339
Research & Development
560.23685.66830.07917.27845.34579.53
Other Operating Expenses
111.04105.8287.9896.4637.96110.64
Operating Expenses
3,7004,1184,2524,3484,1494,027
Operating Income
1,7261,3751,4371,4411,3411,243
Interest Expense
-14.69-32.5-61.28-82.52-64.86-77.39
Interest & Investment Income
47.7158.3491.05107.55107.551,792
Currency Exchange Gain (Loss)
-1.06-1.06-1.07-1.23-1.617.27
Other Non Operating Income (Expenses)
-6.38-14.74-4.37-4.73-71.110
EBT Excluding Unusual Items
1,7521,3851,4611,4601,3112,965
Impairment of Goodwill
---15.88--151.2-
Gain (Loss) on Sale of Investments
-180.84-31.35-213.45-282.81-1,125-79.88
Gain (Loss) on Sale of Assets
-1.798.612.110.15-4.9341.27
Asset Writedown
-140.58-56.95-202.13-1.78-194.64-262.53
Other Unusual Items
35.0839.6736.7845.51-1.9660.04
Pretax Income
1,4641,3451,0691,221-167.632,724
Income Tax Expense
307.72283.89209.63204.46180.82315.92
Earnings From Continuing Operations
1,1561,061859.061,017-348.462,408
Minority Interest in Earnings
67.3643.6396.5354.4384.22-48.75
Net Income
1,2231,105955.591,071-264.242,359
Net Income to Common
1,2231,105955.591,071-264.242,359
Net Income Growth
11.42%15.63%-10.78%--109.51%
Shares Outstanding (Basic)
1,4931,4941,4941,4881,4681,502
Shares Outstanding (Diluted)
1,4931,4941,4941,4881,4681,502
Shares Change
0.55%-0.43%1.34%-2.29%0.08%
EPS (Basic)
0.820.740.640.72-0.181.57
EPS (Diluted)
0.820.740.640.72-0.181.57
EPS Growth
10.81%15.63%-11.16%--109.33%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,5321,0431,4501,9071,8752,229
Free Cash Flow Per Share
1.030.700.971.281.281.48
Dividend Per Share
0.3400.3100.5300.3300.3300.330
Dividend Growth
-17.07%-41.51%60.61%0%0%0%
Gross Margin
67.84%66.70%66.94%66.74%63.56%66.27%
Operating Margin
21.58%16.70%16.91%16.61%15.52%15.63%
Profit Margin
15.29%13.41%11.24%12.35%-3.06%29.66%
Free Cash Flow Margin
19.15%12.67%17.06%21.98%21.71%28.04%
EBITDA
2,0071,7481,9331,9461,7741,648
EBITDA Margin
25.09%21.23%22.75%22.43%20.54%20.72%
D&A For EBITDA
280.86373.14496.2504.91433.92405.08
EBIT
1,7261,3751,4371,4411,3411,243
EBIT Margin
21.58%16.70%16.91%16.61%15.52%15.63%
Effective Tax Rate
21.03%21.10%19.62%16.74%-11.60%
Revenue as Reported
7,9998,2368,4988,6748,637-